阿斯利康：重磅合作，兑现承诺

“进博效应”彰显着中国市场的“全球磁力”，进一步吸引阿斯利康成为坚定加码中国的投资商。进博首日，阿斯利康分别与江苏省、山东省及广东省达成多项合作，继续深化本土布局，夯实在华发展的长期承诺。

The CIIE continues to demonstrate the potential of the Chinese market to the world, further attracting AstraZeneca to become a committed investor determined to expand its investment in China.

On the first day of the CIIE, AstraZeneca reached a number of cooperation agreements with Jiangsu, Shandong and Guangdong respectively, continuing to expand its presence in China and consolidate its long-term commitment to China.

开幕式当天，阿斯利康宣布与江苏省达成一揽子合作协议，包括计划在无锡增资近4亿美元建设小分子药物新工厂，预计未来在国内上市的小分子药物将在无锡新工厂实现从制剂到包装，并供应国内及海外市场。阿斯利康还与泰州医药高新区签署项目投资合作框架协议，持续将泰州打造成为阿斯利康糖尿病产品的全球生产基地，投产后泰州生产供应基地预计年产值将达到100亿人民币。此外，阿斯利康还与无锡高新区、无锡市大数据集团、零氪科技、智众医疗就无锡智慧城市健康大数据展开战略合作。

On the same day as the opening ceremony, AstraZeneca announced a series of cooperation agreements with Jiangsu, including investing an additional $400 million to introduce a new small molecule drug factory in Wuxi.

Through this investment, AstraZeneca plans to cover from formulation to packaging for small molecule drugs approved in China, while supplying both domestic and overseas markets.

Furthermore, AstraZeneca signed a strategic cooperation framework agreement with Taizhou medical high-tech district to establish a new production line, following on from the previous collaboration between AstraZeneca and Taizhou last year to construct another production line.

This ongoing initiative aims to further solidify Taizhou's position as a global production hub for AstraZeneca's diabetes products. After the investment, the Taizhou factory is expected to have an annual output value of 10 billion RMB ($1.37 billion).

‍In addition, AstraZeneca launched the Wuxi Smart City Healthcare Big Data Strategic Cooperation with Wuxi High-tech district, Wuxi Big Data Group, LinkDoc, Zhizhong Medical and Wuxi Smart City Health Big Data.

‍

During the signing ceremony with Jiangsu, four innovative enterprises in the biomedical industry were officially introduced into Wuxi iCampus. At the same time, the Wuxi iCampus (Shanghai) Regional Innovation Centre was unveiled.

Through establishing a science and technology cooperation platform between Wuxi and Shanghai, the Innovation Centre aims to promote the innovative ecosystem in the Yangtze River Delta Area.

In addition, AstraZeneca, Wuxi Industrial Development Group and Wuxi National Hi-tech Zone jointly launched Wuxi iCampus Fund, which will make an equity investment in Synapsor and support Synapsor to implement a city-wide model for the diagnosis and treatment of diabetes in Wuxi.

Looking forward, AstraZeneca will help Synapsor’s products to achieve international development.

当日，阿斯利康还与山东省达成多项签约，包括就青岛吸入气雾剂生产供应基地项目进行了二期项目签约。今年3月，阿斯利康投资4.5亿美元的吸入气雾剂生产基地项目正式落户青岛高新区，8月，阿斯利康又增资2.5亿美元，增加罐装生产能力和新的吸入气雾剂包装生产线，总投资达到7亿美元，将推动青岛工厂成为阿斯利康全球药品供应链的重要一环。

On the same day, AstraZeneca also achieved a number of signings with Shandong, including the signing of the phase II project of AstraZeneca-Qingdao Hi-tech Zone pMDI Inhalation Manufacture Site.

In March this year, AstraZeneca’s inhalation aerosol plant was established in Qingdao Hi-tech Zone with an investment totaling $450 million.  In August, AstraZeneca invested an additional $250 million to increase its packaging can capacity and new packaging lines for inhalation aerosols.

The total $700 million investment further promotes Qingdao to become a critical part of AstraZeneca’s global pharmaceutical supply chain.

此次进博会期间，阿斯利康进一步加深与山东省的合作，与山东省医疗保障局签署战略合作框架协议，双方将在药物上市、医保、商保等方面加强罕见病领域的医疗保障制度合作，助力山东生物医药全产业链开放创新发展。同日，阿斯利康与济南高新区签署罕见病战略合作框架协议，阿斯利康计划在济南高新区建设罕见病合作项目，专注于罕见病研究，致力于开发更多创新药物，以期帮助预防罕见、超罕见和复杂的疾病。此外，青岛国际生命科学创新园iCampus也正式宣布成立，将打造以罕见病及呼吸专科疾病领域特色的主题产业园区，致力于汇集政、产、学、研、医、投的大健康生态圈资源，助力青岛高新区形成健康产业高地。

AstraZeneca also deepened its cooperation with Shandong at this year’s CIIE by signing a strategic cooperation framework agreement with the Healthcare Security Administration of Shandong province.

The two parties will strengthen cooperation in the healthcare security system in areas of drug marketing and sales, medical insurance and commercial insurance, so as to promote the open and innovative development of the entire biopharmaceutical industrial chain in Shandong.

On the same day, AstraZeneca and Ji’nan Hi-tech Zone signed a strategic cooperation framework agreement on rare diseases, under which AstraZeneca plans to build a rare disease cooperation project in Ji’nan Hi-tech Zone, focusing on developing more innovative drugs.

In addition, the establishement of the Qingdao iCampus was announced, featuring an industrial park focusing on rare disease and respiratory disease.

It gradually brings together the big health ecosystem resources of government, industry, academia, research institutes, medical institutions and investment partners to help Qingdao Hi-tech Zone form a healthcare industrial highland.

In addition, AstraZeneca has also reached strategic cooperation agreements with Guangdong, including that for the introduction of AstraZeneca’s drugs in Huangpu District and Guangzhou Development District, and the fast-track market access for its drugs in the GBA in 2023.

With the help of the "Hong Kong and Macao Medicine and Equipment Connect” pilot policy, the fast-track market access of the drugs will improve the early-stage accessibility of drugs that are needed in clinical practice and may enrich the means of medical institutions to deal with diseases.

At the same time, the venture capital fund affiliated to AstraZeneca-Guangzhou Bio-Island Innovation Park was officially launched leveraging the development of the GBA to attract more high-quality “specialized and innovative” companies from home and abroad to settle in Guangzhou.

全球生物制药企业阿斯利康连续六年赴进博之约。本届进博会，阿斯利康延续了1000平米的展台规模，以“三十年，跃行致远 — 在中国，为中国，惠全球”为主题，全面展示在华投资与布局的新进展。

AstraZeneca has participated in the China International Import Expo forsix consecutive years.

This year, AstraZeneca will once again appear with a 1,000-square-meter exhibition booth, holding a "Thirty years, leap to a new future —rooted in China, serving China, benefiting the world" theme that gives an overall picture of the new investment progress in China.

At this CIIE, the main booth will provide a comprehensive introduction to the continued focus AstraZeneca has placed  on disease areas since entering China in 1993.

The exhibition booth showcases 40 innovative drugs that the company has introduced into China, highlighting its contributions in multiple key disease areas. Remarkably, among these accomplishments are innovative medicines that have been introduced through the CIIE over the past five years.